Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Illuminating the role of T cell glycosylation in ankylosing spondylitis
EF 2024-25
Résumé
Ankylosing spondylitis (AS) is an aggressive autoimmune disease that causes chronic inflammation of the joints. Patients suffer from disabling back pain and other comorbidities which compromises their ability to perform everyday tasks and leads to early mortality. There is currently no treatment available that can effectively reduce these symptoms, and clinical diagnosis is often delayed by several years due to a lack of disease-specific biomarkers. As such, we urgently need to identify new therapeutic targets and biomarkers for AS. To realize this, we must first better understand the mechanisms that cause AS.
My research focuses on immune cells called T cells which are considered the primary drivers of AS. Previous studies have shown that T cells in AS patients can infiltrate the joints and initiate inflammation. However, the mechanisms underlying these observations remain unclear. It has been recently shown that carbohydrate structures called glycans can control T cell function and are involved in T-cell mediated autoimmunity. Glycans have been extensively studied in cancers and other autoimmune diseases like multiple sclerosis, where they are currently being tested as therapeutic targets in clinical trials, but they remain unexplored in the context of AS. I hypothesize that glycans may also be relevant in dictating T cell function in AS, and may be useful as biomarkers and therapeutic targets. By analyzing a publicly available RNA sequencing dataset, I have identified 6 candidate glycan-building pathways that may be disrupted in AS. I will use methods such as flow cytometry, western blotting, and proteomics to confirm these differences in AS patients vs. controls (Aim 1) and test if manipulating them is effective in reducing the inflammatory activity of patient T cells (Aim 2). Ultimately, results from my research will identify T cell glycan changes associated with AS and test if it can be clinically useful as biomarkers or therapeutic targets.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518346
Name
Choksi Hani
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Illuminating the role of T cell glycosylation in ankylosing spondylitis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Ankylosing Spondylitis; Autoimmune Diseases; Biochemistry; Glycobiology; Immunology; Molecular Biology; Pharmacology; Rheumatology; Single Cell Analysis; Spectral Flow Cytometry
Abstract
Ankylosing spondylitis (AS) is an aggressive autoimmune disease that causes chronic inflammation of the joints. Patients suffer from disabling back pain and other comorbidities which compromises their ability to perform everyday tasks and leads to early mortality. There is currently no treatment available that can effectively reduce these symptoms, and clinical diagnosis is often delayed by several years due to a lack of disease-specific biomarkers. As such, we urgently need to identify new therapeutic targets and biomarkers for AS. To realize this, we must first better understand the mechanisms that cause AS.
My research focuses on immune cells called T cells which are considered the primary drivers of AS. Previous studies have shown that T cells in AS patients can infiltrate the joints and initiate inflammation. However, the mechanisms underlying these observations remain unclear. It has been recently shown that carbohydrate structures called glycans can control T cell function and are involved in T-cell mediated autoimmunity. Glycans have been extensively studied in cancers and other autoimmune diseases like multiple sclerosis, where they are currently being tested as therapeutic targets in clinical trials, but they remain unexplored in the context of AS. I hypothesize that glycans may also be relevant in dictating T cell function in AS, and may be useful as biomarkers and therapeutic targets. By analyzing a publicly available RNA sequencing dataset, I have identified 6 candidate glycan-building pathways that may be disrupted in AS. I will use methods such as flow cytometry, western blotting, and proteomics to confirm these differences in AS patients vs. controls (Aim 1) and test if manipulating them is effective in reducing the inflammatory activity of patient T cells (Aim 2). Ultimately, results from my research will identify T cell glycan changes associated with AS and test if it can be clinically useful as biomarkers or therapeutic targets.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Choksi, Hani
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~